Educational Reference · Research-Use-Only
BPC-157: Mechanism, Research, and Regulatory Status
A research-grade overview of BPC-157: what it is, how it works at the molecular level, what published studies have shown, and answers to the questions researchers ask most.
Last reviewed 2026-07-28
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, taken from a conserved sequence within the human gastric juice protein BPC. It is unusually stable in gastric acid, plasma, and tissue (hence the name 'stable gastric pentadecapeptide'), which sets it apart from most endogenous peptides. The precise receptor has not been definitively identified.
Several mechanistic pathways have been proposed and characterized in preclinical models. BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and promotes angiogenesis, the growth of new blood vessels, which may underlie its wound-healing effects in tendon, ligament, and muscle tissue. It also modulates nitric oxide (NO) production through both the constitutive (eNOS, nNOS) and inducible (iNOS) nitric oxide synthase isoforms, with context-dependent effects that help restore vascular homeostasis.
BPC-157 activates focal adhesion kinase (FAK) and paxillin, two proteins critical for cell migration, adhesion, and survival. That may explain why it promotes fibroblast and keratinocyte migration in wound models. It also interacts with the GABA-B receptor system, and preclinical data suggest modulation of dopaminergic and serotonergic pathways.
In gastrointestinal research, BPC-157 protects gastric mucosa by suppressing NF-κB, reducing oxidative stress, and maintaining mucosal integrity. It is notable that BPC-157 is active at very low doses (nanogram range) in most preclinical models. All mechanistic and efficacy data are currently from preclinical studies; no completed human clinical trials exist.
Research highlights
What published peer-reviewed research and preclinical studies have established about BPC-157:
- 01Pentadecapeptide stable in gastric juice, plasma, and tissue, and unusually resistant to enzymatic degradation
- 02Extensive preclinical evidence: accelerated healing of tendon (Achilles transection), ligament, muscle (crush injury), bone (critical-size defect), and skin in rodent models
- 03Proposed mechanism: VEGFR2 upregulation driving angiogenesis, FAK-paxillin pathway activation for cell migration, nitric oxide modulation for vascular homeostasis
- 04Cytoprotective GI effects in rodent models of NSAID-induced gastropathy, short bowel syndrome, and inflammatory bowel disease
- 05No completed or published human clinical trials; all data is from preclinical (rat/mouse) models, which limits clinical translation
- 06WADA banned substance (S0: Non-Approved Substances) since 2023, added because of use by athletes despite the absence of any approved therapeutic use
- 07Modulates dopamine and serotonin systems in rodent behavioral models; potential neurological research relevance
Published clinical and preclinical research
Achilles tendon transection (rat model)
Preclinical · 2018BPC-157 (10 μg/kg intraperitoneal) significantly improved load-to-failure, stiffness, and histological tendon organization vs vehicle control; equivalent to local vs systemic delivery
NSAID gastropathy (rat model)
Preclinical · 2011BPC-157 (10–100 ng/kg) reduced indomethacin- and aspirin-induced ulcer area by 60–90% vs vehicle; effects seen via oral, IP, and topical routes
Angiogenesis and vascular repair (in vivo model)
Preclinical · 2014BPC-157 upregulated VEGFR2 expression 3–5x vs control; increased vessel density in ischemic flap models; rescued impaired angiogenesis in nitric oxide deficiency models
Frequently asked questions about BPC-157
Has BPC-157 been tested in human clinical trials?+
As of early 2026, no completed, peer-reviewed, randomized controlled trials of BPC-157 in humans have been published. Sikiric's group at the University of Zagreb has published extensively in rodent models, but no Phase 1/2/3 human data exist in the literature. Investigators at PL10 Therapeutics have registered clinical trials studying a related compound (PL14736, an oral BPC-157 analog) in Crohn's disease, but results have not been published.
Why is BPC-157 on the WADA prohibited list?+
WADA added BPC-157 to its S0 (Non-Approved Substances) list in 2023. S0 prohibits any pharmacological substance that has no current approval by a governmental regulatory health authority for human therapeutic use. WADA added BPC-157 because of increasing use by athletes, not because of established performance-enhancing efficacy. The prohibition does not require proven doping benefit, only that the substance lacks regulatory approval.
What is the reconstitution protocol for BPC-157?+
Reconstitute lyophilized BPC-157 with bacteriostatic water (0.9% benzyl alcohol). Add water slowly down the vial wall; swirl gently. Dissolves readily at 500 mcg/mL to 1 mg/mL concentrations. Solution should be clear and colorless. Store reconstituted solution at 2–8°C for up to 30 days. Some researchers prefer acetic acid (0.1%) as a diluent, which is compatible with BPC-157 for research use.
What routes of administration have been used in preclinical research?+
Preclinical studies have evaluated: intraperitoneal injection, subcutaneous injection, intragastric (oral) administration, and local/topical application. Notably, BPC-157 appears active across all these routes in preclinical models, including oral. That is unusual for peptides, most of which are degraded in the GI tract. This oral stability (due to resistance to gastric enzymes) is proposed as a key feature of BPC-157.
What are the proposed mechanisms for BPC-157's tendon healing effects?+
Preclinical mechanistic data implicate: (1) FAK-paxillin pathway activation promoting fibroblast and tenocyte migration and proliferation; (2) VEGFR2 upregulation driving angiogenesis (new blood vessel formation to the healing tendon); (3) upregulation of early growth response protein 1 (Egr-1), a transcription factor driving tendon-specific matrix gene expression; (4) normalization of NO system activity in ischemic tendon tissue.
Can BPC-157 be stacked with TB-500 (Thymosin Beta-4) in research?+
TB-500 (a fragment of thymosin beta-4) and BPC-157 are often studied in combination by researchers interested in tissue repair. The compounds have distinct and potentially complementary mechanisms: BPC-157 primarily targets angiogenesis and FAK/paxillin pathways, while TB-500 (Tβ4) acts via actin polymerization regulation and VEGF-mediated effects. Combination protocols are not supported by published clinical data. All combination research is preclinical or anecdotal.
What is the storage stability of BPC-157?+
Lyophilized BPC-157 is stable for 24+ months at −20°C in properly sealed, desiccated vials. The peptide sequence (15 amino acids) has no disulfide bonds, which reduces oxidative degradation risk. Primary stability concerns are moisture absorption (use desiccant packs during storage) and repeated thermal cycling. After reconstitution, use within 28–30 days when stored at 2–8°C.
What GI conditions has BPC-157 been studied for in preclinical models?+
Preclinical models where BPC-157 showed efficacy include: NSAID-induced gastric ulcers, alcohol-induced gastric lesions, short bowel syndrome (intestinal anastomosis healing), inflammatory bowel disease (acetic acid colitis model), fistula healing, and cytoprotection against chemotherapy-induced intestinal damage. The range of GI effects has driven interest in oral BPC-157 analogs for human GI disease, though human data remain unpublished.
References & sources
Every citation below was resolved against its primary source before publication. Each PMID was checked against its PubMed record and each DOI through doi.org. Follow any link to read the paper at the publisher rather than taking our summary on trust.
- [1]Sikiric P, Hahm KB, Blagaic AB, et al. Pentadecapeptide BPC 157, wound healing, and the Achilles tendon. Current Pharmaceutical Design. 2018. PMID: 29737246 DOI: 10.2174/1381612824666180501094029
- [2]Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014. PMID: 24345416 DOI: 10.2174/13816128113199990421
- [3]Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011. PMID: 21861804 DOI: 10.2174/138161211796197205
- [4]Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2013. PMID: 23448467 DOI: 10.2174/1381612811319050016
- [5]Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011. PMID: 21030675 DOI: 10.1152/japplphysiol.00945.2010
- [6]Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003. PMID: 12564124 DOI: 10.1016/S0736-0266(02)00110-4
- [7]Sikiric P, Rucman R, Seiwerth S, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Current Pharmaceutical Design. 2018. PMID: 29141554 DOI: 10.2174/1381612823666171110105939
Where this data comes from
- Citations & trial data: PubMed (NCBI, U.S. National Library of Medicine), Crossref and ClinicalTrials.gov.
- Chemical identity: PubChem and UniProt. Where sources conflicted, the disputed value is omitted rather than guessed.
- Regulatory status: U.S. FDA publications and, where applicable, the WADA Prohibited List. Compounding status changes often, so check FDA directly before relying on it.
- Purity, form and storage are handling and supplier conventions, not literature-derived values. Confirm against the lot-specific certificate of analysis.
Content last reviewed 2026-07-28. Compiled by Veridian Research from the primary literature. This page is an educational reference for laboratory researchers. It is not medical advice, and it describes no human use.
Regulatory status
BPC-157 is an investigational peptide with no approved therapeutic use in any jurisdiction. No completed human clinical trials have been published. WADA added BPC-157 to its S0 Prohibited List (Non-Approved Substances) in 2023. For research purposes only.
Research-Use-Only Material
Specifications and certificate of analysis
BPC-157 is stocked as a research reagent. The most recent batch (2026-03) was analysed by Janoshik Analytical at >=99% purity; the signed certificate is published in full.